Clinical Trial Detail

NCT ID NCT02736123
Title Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Pittsburgh
Indications

melanoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.